Nutex Health's stock is rated Buy with a price target of $199.31, suggesting a 19.8% gain from its current price of $166.40. The company’s revenue jumped significantly from $247.6 million in fiscal 2023 to $880 million trailing twelve months ending March 31, 2026, driven by effective use of the No Surprises Act’s IDR process. Financial metrics have improved, with debt-to-equity ratio dropping below 1.0 and a strong current ratio of 3.1. Despite risks like regulatory challenges, late filings, reverse stock splits, and a high short interest of 16.21%, Nutex Health’s profitability and valuation remain attractive for investors.
Societe Generale has announced the launch of a new Senior Preferred bond issuance with two tranches maturing in July 2028 and July 2031. This issuance is part of the bank's 2026 long-term funding program, aiming to support its financial stability and...
Abivax, a clinical-stage biotech company, has temporarily suspended trading of its ordinary shares on Euronext Paris starting July 1, 2026, at 9:00 CEST. This suspension is at Abivax's request to facilitate the confirmation of allocations and final t...
Sanofi has released its Q2 2026 aide-mémoire document on its investor website to assist financial modeling for the upcoming quarterly results. This memo includes details on non-comparable items, currency impacts, and share count. The full Q2 2026 ear...
The global human fibrinogen concentrate market is projected to grow from approximately $0.95 billion in 2025 to $2.78 billion by 2035, at a compound annual growth rate (CAGR) of 11.3%. This growth is fueled by increasing cases of bleeding disorders, ...
Forward Industries, Inc. announced that as of July 1, 2026, it has 73,846,883 common shares outstanding after repurchasing 13,316,224 shares. The company also has outstanding options to purchase 1,811,666 shares, restricted and performance stock unit...
